康希诺生物发布2025年度业绩快报 归母净利润2787.27万元,同比扭亏为盈
智通财经网·2026-02-26 08:57

Core Viewpoint - The company reported a significant improvement in financial performance for the fiscal year 2025, with total revenue increasing by 26.18% year-on-year and achieving a net profit attributable to shareholders for the first time [1][2] Financial Performance - Total revenue reached 1.068 billion RMB, marking a year-on-year growth of 26.18% [1] - The net profit attributable to shareholders was 27.8727 million RMB, indicating a turnaround from a loss to profit [1][2] - Basic earnings per share were reported at 0.11 RMB [1] Operational Efficiency - The company implemented cost reduction and efficiency enhancement measures, leading to effective expense management [1][2] - The gross profit margin improved due to optimized production and sales coordination [1] Research and Development - The company continued to advance its R&D projects and international collaborations, receiving government grants and international R&D funding [1] - Non-recurring income related to these grants was recognized during the reporting period [1] Share Capital - The company's share capital was approximately 247 million shares at the end of the reporting period, a decrease of about 410,000 shares due to the cancellation of previously repurchased A-shares [2]

CANSINOBIO-康希诺生物发布2025年度业绩快报 归母净利润2787.27万元,同比扭亏为盈 - Reportify